Please login to the form below

Not currently logged in
Email:
Password:

Pharmacoeconomic

This page shows the latest Pharmacoeconomic news and features for those working in and with pharma, biotech and healthcare.

Get Real! The Rise of Observational Data In Healthcare

Get Real! The Rise of Observational Data In Healthcare

safety across the treated patient population for pharmacovigilance purposes and can also provide additional pharmacoeconomic insights, for example looking at the use of resources or financial considerations. ... Pfizer recently set up a specialised unit -

Latest news

  • Antibiotics: pharma's Cinderella story Antibiotics: pharma's Cinderella story

    Finally, can the agents which promise rapid infection resolution and the potential of patient management outside the hospital setting create compelling pharmacoeconomic arguments to justify premium pricing?

  • Questions raised about affordability of asthma antibodies Questions raised about affordability of asthma antibodies

    GSK meanwhile says it is confident that pharmacoeconomic studies will prove the worth of biologics in reducing hospitalisations and the significant morbidity associated with oral steroid use.

  • Genzyme continues MS drug rollout across EU Genzyme continues MS drug rollout across EU

    The launch of Lemtrada follows a recommendation in July this year from the National Centre for Pharmacoeconomics (NCPE), which provides guidance on what drugs should be reimbursed on Ireland's healthcare

  • Taking contract research’s pulse Taking contract research’s pulse

    They are also seeing increased demand for pharmacoeconomic end points in trials and comparative effectiveness research (CER) to help meet payers' increasing demands on patient outcomes.

  • All eyes on pharma in Brazil All eyes on pharma in Brazil

    The Government will pay for specialised, new and expensive drugs but companies have to submit an HTA dossier complete with pharmacoeconomic analyses similar to those required by NICE.

More from news
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • Plugging knowledge gaps to demonstrate the benefits of new medicines

    Hayward Medical Communications recently presented a poster, titled The use of consensus techniques to inform health technology appraisals, at the 19th Annual European Conference of the International Society for Pharmacoeconomics and

  • The heart of the matter - Part Three

    That's incorrect. RWE is not just about the product – it's about understanding the disease burden and unmet need in your target area, to help you establish pharmacoeconomic and outcomes

  • What's the Big Idea?

    Think of areas such as R&D, clinical trials, marketing, pharmacoeconomics, and pharmacoepidemiology - and the floods of data that they produce.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics